An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma Review

   


Authors: Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
Review Title: An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
Abstract: In the past year, three new bispecific antibodies have received accelerated FDA approval for the treatment of relapsed/refractory multiple myeloma. In this article, we review the available data for these three agents, teclistamab, elranatamab, and talquetamab, and discuss practical considerations for their use in clinical settings while the medical community awaits randomized phase III clinical trial datasets comparing them to standard-of-care regimens. ©2023 American Association for Cancer Research.
Keywords: antineoplastic agents; antineoplastic agent; multiple myeloma; antineoplastic combined chemotherapy protocols; antibodies, bispecific; bispecific antibody; humans; human; embarrassment
Journal Title: Blood Cancer Discovery
Volume: 4
Issue: 6
ISSN: 2643-3230
Publisher: American Association for Cancer Research  
Date Published: 2023-11-01
Start Page: 433
End Page: 436
Language: English
DOI: 10.1158/2643-3230.Bcd-23-0176
PUBMED: 37824758
PROVIDER: scopus
PMCID: PMC10618718
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85175741621&doi=10.1158%2f2643-3230.BCD-23-0176&partnerID=40&md5=72505f40d9bcffcbe12ac786cfffb8b9
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Alexander Meyer Lesokhin
    374 Lesokhin
  2. Saad Zafar Usmani
    327 Usmani
  3. Ross Firestone
    40 Firestone
Related MSK Work